Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis  by Shang, Yulei & Huang, Eric J.
Brain Research 1647 (2016) 65–78Contents lists available at ScienceDirectBrain Researchhttp://d
0006-89
n Corr
United S
E-mjournal homepage: www.elsevier.com/locate/brainresMechanisms of FUS mutations in familial amyotrophic lateral sclerosis
Yulei Shang a, Eric J. Huang a,b,n
a Department of Pathology, University of California San Francisco, San Francisco, CA, United States
b Pathology Service 113B, VA Medical Center, San Francisco, CA, United Statesa r t i c l e i n f o
Article history:
Received 11 January 2016
Received in revised form
22 March 2016
Accepted 24 March 2016
Available online 28 March 2016
Keywords:
RNA binding protein
Fused in sarcoma (FUS)
Prion-like property
Low complexity domain
DNA damage repair
RNA splicing
Amyotrophic lateral sclerosis (ALS)
Frontotemporal dementia (FTD)x.doi.org/10.1016/j.brainres.2016.03.036
93/& 2016 The Authors. Published by Elsevie
espondence to: Department of Pathology, U
tates.
ail address: eric.huang2@ucsf.edu (E.J. Huang)a b s t r a c t
Recent advances in the genetics of amyotrophic lateral sclerosis (ALS) have provided key mechanistic
insights to the pathogenesis of this devastating neurodegenerative disease. Among many etiologies for
ALS, the identiﬁcation of mutations and proteinopathies in two RNA binding proteins, TDP-43 (TARDBP
or TAR DNA binding protein 43) and its closely related RNA/DNA binding protein FUS (fused in sarcoma),
raises the intriguing possibility that perturbations to the RNA homeostasis and metabolism in neurons
may contribute to the pathogenesis of these diseases. Although the similarities between TDP-43 and FUS
suggest that mutations and proteinopathy involving these two proteins may converge on the same
mechanisms leading to neurodegeneration, there is increasing evidence that FUS mutations target dis-
tinct mechanisms to cause early disease onset and aggressive progression of disease. This review focuses
on the recent advances on the molecular, cellular and genetic approaches to uncover the mechanisms of
wild type and mutant FUS proteins during development and in neurodegeneration. These ﬁndings
provide important insights to understand how FUS mutations may perturb the maintenance of dendrites
through fundamental processes in RNA splicing, RNA transport and DNA damage response/repair. These
results contribute to the understanding of phenotypic manifestations in neurodegeneration related to
FUS mutations, and to identify important directions for future investigations.
This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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1.1. The expanding genetic landscape of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurode-
generative disease that affects upper and lower motor neurons. As
initially described by Jean-Martin Charcot more than 140 years
ago, the key clinical features in ALS patients include muscle
wasting, and progressive loss of spinal motor neurons and upper
motor neurons and their axons in the lateral columns of the spinal
cord. Recent advances in human genetics have identiﬁed many
genetic loci that are mutated in patients with familial ALS (FALS).
Among a growing number of genes involved in FALS, mutations in
four genes account for the majority of cases. These mutations in-
clude missense mutations in superoxide dismutase 1 (SOD1), two
genes encoding RNA/DNA binding proteins, TDP-43 (TARDBP or
TAR-DNA-binding protein-43) and FUS/TLS (fused in sarcoma/
translocation in liposarcoma or FUS), and the GGGGCC hex-
anucleotide expansions in C9ORF72 gene (Cirulli et al., 2015; Lee
et al., 2012; Ling et al., 2013). The discovery of TDP-43 as a major
component in the ubiquitin-positive, tau-negative insoluble pro-
tein aggregates in neurons and glia represents a major break-
through in FTD (frontotemporal dementia) and ALS research (Arai
et al., 2006; Neumann et al., 2006). Moreover, the impact of this
discovery goes beyond the identiﬁcation of a single disease gene
and essentially ushers in a new era of research that focuses on the
potential contributions of transcription, RNA splicing and RNA
metabolism on neurodegenerative diseases.
TDP-43 is originally identiﬁed to bind to the TAR DNA sequence
in HIV-1 genome to regulate viral gene expression (Ou et al., 1995).
Under physiological conditions, TDP-43 is a ubiquitous nuclear
protein, however, in FTD patients, TDP-43 aggregates are present
predominantly in neuronal cytoplasm and dystrophic neuronal
processes (Arai et al., 2006; Neumann et al., 2006). This distinct
feature, deﬁned as TDP-43 proteinopathy, constitutes a major
neuropathological diagnosis entity in sporadic ALS (ALS-TDP).
Several subsequent studies show that dominant mutations in the
TARDBP gene can also be identiﬁed in FALS patients (Lattante et al.,
2013). The identiﬁcation of autosomal dominant mutations in the
FUS gene in a large kindred of familial ALS (FALS) further expanded
the genetic and neuropathological landscape of ALS (Kwiatkowski
et al., 2009; Vance et al., 2009). Similar to TDP-43, FUS proteins
reside primarily in the neuronal nuclei, but in ALS-FUS patients
FUS proteins form large aggregates in the cytoplasm. The mor-
phology of FUS proteinopathy in FALS ranges from diffuse and
dense cytoplasmic aggregate present in late onset cases, to baso-
philic inclusions commonly found in juvenile FALS with FUS-
P525L mutation. Finally, in 2011 two groups independently re-
ported the GGGGCC hexanucleotide repeat expansions in the
noncoding region of the C9ORF72 gene as causal links to ALS and
FTD (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Although
TDP-43 proteinopathy can be detected in FTD and ALS patients
with C9ORF72 mutations, the neuropathological features in these
cases are quite heterogeneous and also include prominent ubi-
quitin and p62 positive, but TDP-43 negative intracytoplasmic and
intranuclear inclusions (Bigio, 2012; Mackenzie et al., 2014).1.2. Early disease onset in FALS caused by FUS mutations
It is estimated that mutations in TARDBP and FUS each account
for 5% of FALS, whereas the GGGGCC expansion mutations in
C9ORF72 account for 20–40% of ALS and FTD-ALS cases, depending
on the population studied (Cirulli et al., 2015). One important
feature noted in a recent study indicates that the age of disease
onset for FALS caused by FUS, TARDBP and C9ORF72 mutations
differ quite drastically. Mutations in FUS account for 35% of FALS
in patients younger than 40 years old, whereas mutations in
C9ORF72 are much more common in patients older than 50 years
of age (Millecamps et al., 2012). Indeed, meta-analyses of 154 ALS
cases with FUS mutations (including FALS and SALS with de novo
FUS mutations) show an average disease onset of 43.8717.4 years
(Fig. 1) (Deng et al., 2014a; Lattante et al., 2013). More than 60% of
cases with FUS mutations show disease onset before 45 years of
age, with many juvenile ALS cases presenting with disease onset in
late teens and early 20's (Fig. 1) (Baumer et al., 2010; Huang et al.,
2010). These ﬁndings are similar to those from another study using
smaller sample size, and show that the average disease onset for
FUS, SOD1 or TARDBP mutations is 43.6715.8, 47.7713.0 and
54.7715.3, respectively (Yan et al., 2010). Kaplan–Meier survival
analysis shows statistically signiﬁcant differences in the age of
onset among these three mutations. This distinctive feature of FUS
mutations raises the intriguing hypothesis that mutations in FUS
may target divergent mechanisms that perturb the development,
maintenance and homeostasis of the nervous system in early
postnatal life and in the aging process.
This review focuses on the recent progress on the molecular,
cellular and genetic approaches to uncover the mechanisms of
wild type and mutant FUS proteins. These ﬁndings provide im-
portant insights to understand how FUS mutations may perturb
the fundamental processes in DNA damage response/repair, RNA
splicing, and RNA transport, to interpret the phenotypic manifes-
tations in neurodegeneration related to FUS mutations, and to
identify important directions for future investigations.2. Physical properties of FUS and their implications in RNA
metabolism
2.1. RNA binding properties of FUS
FUS is identiﬁed as an oncogene that undergoes chromosomal
translocation in myxoid liposarcoma, in which the N-terminal
transcriptional activation domain of FUS is fused to CHOP (CAAT
enhancer-binding homologous protein), a growth arrest and DNA-
damage inducible member of the C/EBP family of transcription
factors (Crozat et al., 1993; Rabbitts et al., 1993). Subsequent stu-
dies further reveal that chromosomal translocations involving FUS
can be identiﬁed in several other human cancers, including acute
myeloid leukemia, where the N-terminus of FUS gene is translo-
cated to the ERG gene, a member of the ETS transcription factor
family (Ichikawa et al., 1994; Prasad et al., 1994). Structurally, FUS
belongs to a family of FET RNA binding proteins, including FUS,
Ewing's sarcoma RNA binding protein 1 (EWSR1) and Tata-binding
protein-associated factor 2N (TAF-15), that are known to interact
with the C-terminal domain of RNA polymerase II (RNAP II) and
Fig. 1. The age of disease onset in FALS patients with FUS mutations. (A) Meta-analyses of 154 FALS patients (either familial ALS inherited mutations or sporadic ALS with de
novo mutations) show a predilection early disease onset. Compared to all FUS mutations and the most common mutations that occur in amino acid 521 (FUS-R521C), FUS-
P525L mutation tends to occur in late teens and early 20's and represents a much more aggressive form of disease. (B) For sporadic ALS (SALS), about 35.9% and 34.9% of
patients show disease onset in the range of 41–55 and 56–65 years old. In contrast, more than 60% of ALS patients with FUS mutations show disease onset before 40 years
old. *Statistics for SALS have been adapted from the study by Testa and colleagues (Testa et al., 2004).
Fig. 2. Schematic diagrams of genomic organization of the human FUS Gene, FUS mutations identiﬁed in ALS, and functional domains in FUS proteins. The human FUS gene
consists of 15 exons, spanning 14.9 Kb, and is located on chromosome 16p11.2. The FUS mRNA transcripts are predicted to contain a 3,433 bp 3'UTR, which has been
recently shown to contain 4 disease-related variants. The full length human FUS protein contains 526 amino acids that can be further divided into several functional
domains, including the “prion-like” or low complexity (LC) domain that contains the Q/G/S/Y-rich region (amino acids 1–165) and the G-rich region (amino acids 165–267),
the Arginine-rich motif (RRM, amino acids 285–371), two Arg-Gly-Gly (RGG)-repeat regions (amino acids 371–422 and 453–501), interrupted by a Cys2–Cys2 zinc-ﬁnger motif
(ZNF)(amino acids 422–453), and a non-conventional nuclear localization signal (NLS)(amino acids 510–526). The majority of FALS-related mutations are more commonly
found in (1) the G-rich region, (2) the 2nd RGG region and (3) the NLS. Additional structural and functional domains in FUS include the prion-like domains and the HDAC1-
interacting domains.
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2013; Schwartz et al., 2012; Tan and Manley, 2009). Full length
human FUS protein contains 526 amino acids that can be divided
into the N-terminal “prion-like” or low complexity (LC) Q/G/S/Y
domain (amino acids 1–165) and Gly-rich region (amino acids
166–267)(Fig. 2). The C-terminal half of FUS protein contains an
RNA recognition motif (RRM)(amino acids 285–371), two Arg-Gly-
Gly (RGG)-repeat regions (amino acids 371–422 and 453–501),
interrupted by a Cys2–Cys2 zinc-ﬁnger motif (ZNF)(amino acids
422–453), and a non-conventional nuclear localization signal
(NLS)(amino acids 510–526), which interacts with the nuclear
transport receptor Transportin 1 (Fig. 2) (Dormann et al., 2012,
2010; Iko et al., 2004). Most of the FALS-associated FUS mutations
cluster in the N-terminal LC domain, the second RGG domain and
NLS in the C-terminal (Fig. 2).
Following its discovery as an oncogene involved in chromoso-
mal translocation in malignant tumors, several studies have elu-
cidated the biochemical properties of FUS as an RNA binding
protein that regulates splicing. First, by UV cross-linking, it has
been shown that FUS can bind to RNA. The binding seems not to
depend on the RRM in the C-terminus, but rather on the zinc
ﬁnger (ZnF) motif (Iko et al., 2004; Zinszner et al., 1997). Second,
FUS is an abundant nuclear protein that can form stable complex
with many members of the heterogeneous ribonuclear protein
(hnRNP) family and can be co-puriﬁed from nuclear extracts by
single-stranded DNA afﬁnity chromatography (Calvio et al., 1995;
Zinszner et al., 1994, 1997). One study suggests that the stability of
the FUS-hnRNP complex is dependent on the integrity of its con-
stituent RNA (Zinszner et al., 1994). While these results do not
prove that FUS can directly interact with RNA, they suggest that at
least some component(s) of the FUS-hnRNP complex has RNA-
binding activity.
To further determine if FUS directly binds to speciﬁc RNA se-
quence, Lerga and colleagues use an in vitro selection assay and
identify a common GGUG motif in RNA oligoribonucleotides that
bind to recombinant FUS protein (Lerga et al., 2001). These results
are veriﬁed using UV cross-linking combined with competition
and immunoprecipitation in nuclear extracts. The ability of FUS to
directly interact with RNA has been further examined using in FUS
antibody immunoprecipitates from mouse and human brain tis-
sues, followed by CLIP (cross-linking immunoprecipitation)-RNA
sequencing (CLIP-Seq) (Lagier-Tourenne et al., 2012). This ap-
proach shows that both mouse and human FUS proteins bind to
RNAs that contain an enriched GUGGU motif, different from the
GU-rich binding sequence reported for TDP-43 (Polymenidou
et al., 2011; Tollervey et al., 2011). However, several studies using
similar CLIP-seq technology do not ﬁnd similar consensus RNA
binding sequences for FUS (Colombrita et al., 2012; Hoell et al.,
2011; Ishigaki et al., 2012; Rogelj et al., 2012). Instead, the results
from these studies support the idea that FUS binding sites in RNA
tend to form stable secondary structures, such as the stem-and-
loop structure (Hoell et al., 2011; Ishigaki et al., 2012). Similarly,
FUS has also been shown to interact with the short RNA repeats r
(UUAGGG) in the G-quadruplex telomeric repeat-containing RNA
(TERRA) by forming unique secondary and tertiary structures
(Takahama et al., 2013). In a recent study, Wang and colleagues
examine the speciﬁcity of the putative FUS-binding RNA motifs
using electrophoretic mobility shift assays (EMSA), and show that
FUS binds to all the repeats with Kd values within a 10-fold range
(Wang et al., 2015). Surprisingly, RNAs without any of the reported
binding motifs also bind to FUS with similar afﬁnity. Together,
these results support that the nucleic acid binding property in FUS
can be rather generic or “promiscuous”, and is likely dictated by
the secondary or tertiary structure of RNA.2.2. Roles of FUS in RNA splicing
Given the nature of FUS–RNA interactions, what would be the
physiological role of FUS in RNA metabolism? Previous CLIP-seq
studies show that most RNAs that bind to FUS contain intronic
sequences. Perhaps the most unique feature is that in genes with
long intron, FUS-RNA binding exhibits a distinct “sawtooth” CLIP
pattern (Lagier-Tourenne et al., 2012; Rogelj et al., 2012), with
substantially higher FUS cluster density at the beginning of introns
and a gradual decrease toward the 3’ sequence. These results
suggest that FUS is co-transcriptionally deposited onto the nascent
RNA transcripts. In addition, FUS binding has been identiﬁed
around the alternatively spliced exons and in the promoter anti-
sense strands in several genes implicated in neurodevelopmental
and neurodegenerative diseases (Ishigaki et al., 2012), suggesting
that FUS may involve in alternative splicing and transcription. The
support for FUS in RNA splicing is further underscored by the
identiﬁcation of FUS as an direct interacting partner with splicing
factors, SC35 and SRSF10 (serine/arginine-rich splicing factor 10),
and as one of the 50 non-snRNP proteins in the pre-spliceosome
(Behzadnia et al., 2007; Wahl et al., 2009; Yang et al., 1998). While
these results provide physical evidence of FUS in RNA splicing, it
remains unclear how FUS regulates the recognition of the 5′ splice
junction, the formation and stability of Complex A, and the efﬁ-
ciency of splicing. Finally, two studies use epitope-tagged FUS to
identify FUS interactome in nuclear extracts from HeLa cells and
show that FUS can also interact with SMN and U1 snRNP (Sun
et al., 2015; Yamazaki et al., 2012). The results that FUS can interact
with SMN is intriguing because SMN is implicated in fatal child-
hood motor neuron disease spinal muscular atrophy (SMA) and
the organization of Gemini of Cajal bodies (Gems). Consistent with
these ﬁndings, knocking down FUS or expression of FALS-asso-
ciated FUS mutant proteins severely compromise the formation of
Gems in HeLa cells and ﬁbroblasts from FALS patients, respectively.
In primary neurons, FALS-associated FUS mutant proteins promote
SMN protein aggregation in the cytoplasm and axons of primary
neurons (Groen et al., 2013; Yamazaki et al., 2012). In a recent
study, Sun and colleagues further show that the RGG domain in
FUS and the Tudor domain in SMN are required for direct inter-
action. Surprisingly, FALS-associated FUS mutations enhance the
interaction between FUS and SMN, and thereby affecting the
normal functions of SMN by reducing Gems bodies and changing
the state steady level of snRNA in transgenic mouse tissues and in
ﬁbroblasts from patients expressing mutant FUS proteins (Sun
et al., 2015). Global analysis of RNA splicing reveals that mutant
FUS-dependent splicing changes mimic partial FUS loss of activity,
independent of cytosolic mislocalization. These results provide
evidence for both gain and loss of function caused by ALS-linked
mutations in FUS and the potential convergence in pathological
pathways of ALS and SMA.
2.3. Prion-like property of FUS and its implication in liquid-to-solid
phase transition
The presence of TDP-43 and FUS proteinopathy in ALS raises
the intriguing possibility that TDP-43 and FUS may have a high
propensity to form protein aggregates. Indeed, using a bioinfor-
matics algorithm designed to identify proteins with “prion-like” or
low complexity (LC) domain (Alberti et al., 2009), it has been
shown that the N-terminal Q/G/S/Y domain and part of the Gly-
rich region in FUS (amino acids 1–239) and the C-terminal Gly-rich
region of TDP-43 (amino acids 277–414) respectively rank 15th
and 69th among 27,879 proteins in the human proteome for their
prion-like property (Cushman et al., 2010; Gitler and Shorter,
2011) (Fig. 2). Consistent with this idea, expression of TDP-43 and
FUS in the baker's yeast Saccharomyces cerevisiae shows that both
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proteinopathy in human diseases and that the protein aggregate
formation is dependent on the prion-like domains (Fushimi et al.,
2011; Sun et al., 2011). These ﬁndings underscore the value of
yeasts as a model organism that can be used for genetic screens to
identify modiﬁers that can alleviate FUS proteinopathy. Indeed,
such screens reveal many potential candidates that are implicated
in RNA metabolic process, ribosome biogenesis, response to cel-
lular stress, etc (Sun et al., 2011). Similar approach has also been
exploited as an effective screen to identify the causal links be-
tween two other FET family members, EWSR1 and TAF15, to the
pathogenesis of ALS (Couthouis et al., 2012, 2011). Several other
RNA-binding proteins with similar prion-like properties have been
implicated in the organization of stress granules and perturbations
to this process may also contribute to ALS and other neurode-
generative diseases (Li et al., 2013).
One major advance in understanding the biophysical property
of FUS and its role in the formation of RNA granules comes from
the observation of a small molecule chemical 5-aryl-isoxazole-3-
carboxyamide, which when biotinylated acquires the unique
property to aggregate and disaggregate RNA granules in a soluble,
cell-free system (Han et al., 2012; Kato et al., 2012). Using bioti-
nylated isoxazole (b-isox), McKnight and colleagues use an elegant
and highly efﬁcient hydrogel formation assay and identify that
several RNA binding proteins, including FUS, TDP-43, and
hnRNPA1, have a high propensity to co-precipitate with b-isox
using their LC domain. Many of these proteins have been im-
plicated in the formation of stress granules. Consistent with this
idea, mutations that alter the highly conserved [G/S]Y[G/S] motif
within the LC domain of FUS completely abolish its ability to form
stress granules in cells. The authors use transmission electron
microscopy (TEM) and X-ray diffraction analyses to show that FUS
form amyloid-like ﬁlamentous protein aggregates with prominent
ﬁlamentous cross-β structure that resembles amyloid proteins.
Indeed, both biophysical measurements and ultrastructural ana-
lyses show that the ﬁbrillary FUS proteins in the hydrogel re-
semble FUS aggregates identiﬁed in the cytoplasm of spinal motor
neurons in a patient with FUS-P525L mutation using immunogold
EM (Huang et al., 2010; Kato et al., 2012).
Knowing the unique property of FUS in hydrogel formation,
one critical and intuitive question is how FALS-associated muta-
tions in FUS might alter the biophysical properties of FUS and
thereby affects the function of FUS in RNA-protein complex for-
mation. To investigate this, Alberti and colleagues show that when
cells experience DNA damage or heat stress, FUS rapidly accu-
mulates in distinct compartments in the nucleus and cytoplasm,
respectively. They then use an imaging technique, known as “half-
bleach” (Brangwynne et al., 2009), to show that FUS redistributes
rapidly within stress granules in the cytoplasm and in nuclear FUS
assemblies. Their results show that FUS granules undergo frequent
fusion, and as soon as they interact, these granules undergo rapid
relaxation into a spherical shape (Patel et al., 2015). These results
indicate that the FUS-containing compartments, which exist in
liquid droplets and hydrogel states, are reversible and extremely
dynamic. Interestingly, FUS mutations associated with FALS pro-
mote a conversion of FUS-containing liquid droplets to ﬁber state,
which results in impaired protein synthesis in axons and leads to
neurotoxicity (Murakami et al., 2015; Patel et al., 2015).
2.4. LC domain of FUS in high-order assembly of protein-RNA
complex
The ability of FUS to form RNA-protein complexes is further
revealed using a 48 nucleotide (nt)-long RNA (prD RNA) from the
promoter region of DNMT3b gene (Schwartz et al., 2012, 2013). It
is important to note that this prD RNA does not contain any of thepreviously identiﬁed FUS binding motifs (Lagier-Tourenne et al.,
2012; Lerga et al., 2001), yet exhibit robust binding to recombinant
FUS proteins in electrophoretic mobility shift assays (Schwartz
et al., 2013). This provides a convenient tool to characterize the
essential role of the LC domain in FUS and its mutual interactions
with RNA to form high-order protein-RNA complexes. Similar
high-order assemblies have been reported using recombinant FUS
proteins and synthetic RNA from the intron-exon boundary and
3’UTR of the bdnf gene (Qiu et al., 2014). Many of these bdnf RNA
probes do not contain the reported FUS binding motif, again
supporting the notion that the RNA structure is perhaps more
important for FUS interaction. Interestingly, RNA-FUS assemblies
appear to be critical for its interaction with the CTD of RNA poly-
merase II (Schwartz et al., 2013).
Using the FUS-bdnf RNA interactions, Qiu and colleagues show
that mutant FUS-R521C proteins form more stable and higher
order protein-RNA assemblies, which are more difﬁcult to dis-
sociate in competition assays (Qiu et al., 2014). Interestingly, in
transgenic mice expressing FUS-R521C, the majority of mutant FUS
proteins are in the nuclei of spinal motor neurons, suggesting that
the presence of high-order mutant FUS-RNA assemblies may in-
terfere with the transcription and/or RNA splicing. Consistent with
these results, expression of mutant FUS proteins or siRNA knock-
down of FUS in ﬁbroblasts alters the distribution of RNA poly-
merase II within the nuclei. These results are further conﬁrmed
using ﬁbroblasts derived from FALS patients with FUS mutations
(Nomura et al., 2014; Schwartz et al., 2014).3. FUS mutations and neurodegeneration in model organisms
3.1. Dendrite and synaptic defects in rodent models of FUS mutations
To characterize the consequences of expressing mutant FUS
proteins in the nervous system, several groups have used a num-
ber of transgenic strategies in mice or rats to model disease con-
ditions caused by FUS mutations. Results from these studies show
that expressing mutant FUS proteins causes consistent neurode-
generative phenotypes. For instance, both the transgenic mouse
and rat models expressing mutant FUS-R521C proteins develop
early onset ALS-like symptoms, including hindlimb paralysis,
muscle wasting, and reduced innervation at the neuromuscular
junction (NMJ) (Huang et al., 2011; Qiu et al., 2014; Sharma et al.,
2016). The cardinal phenotypes include age-dependent reductions
in dendritic arborization and synaptic density in the spinal motor
neurons and cortical neurons in the sensorimotor cortex of the
FUS-R521C transgenic mice (Fig. 3) (Qiu et al., 2014). Similar
dendritic arborization defects have also been reported in neurons
in the entorhinal cortex of Camk2a-tTA transgenic rats (Huang
et al., 2012), and in the spinal motor neurons and cortical neurons
of Cre-inducible transgenic mouse lines that express FUS-R521G in
the nervous system (Sephton et al., 2014). The dendritic phenotype
caused by FUS-R521C can be recapitulated in cultured cortical
neurons, and partially rescued by exogenous BDNF (Qiu et al.,
2014). In side-by-side comparisons, FUS-R521C and FUS-P525L
cause more severe dendritic growth defects compared to wild type
FUS. These results support the notion that wild type and mutant
FUS affect dendritic growth in gene dosage-dependent manner. In
light of these ﬁndings, it is interesting to note that transgenic mice
expressing higher level of wild type FUS also show early onset
motor neuron degeneration in a dosage-dependent manner
(Mitchell et al., 2013). Consistent with these results, mutations in
the 3′ UTR of the FUS gene have been identiﬁed in several FALS
patients. These mutations drastically increase the FUS protein
expression in the patients’ ﬁbroblasts, at levels higher than that in
FUS-R521C ﬁbroblasts (Sabatelli et al., 2013), supporting the
Fig. 3. Dendritic and synaptic phenotypes caused by FUS mutations. Neurolucida tracing shows that the dendritic arbors in control motor neurons, highlighted by Golgi
staining techniques, had 6 to 8 intersections per radial distance within 100 μm from the cell body, followed by a gradual reduction in the number of dendritic arbors from 100
to 250 μm. Compared to the control, the number of dendritic arbors in the FUS-R521C motor neurons shows no change within the ﬁrst 50 μm from the cell body, but a
signiﬁcant reduction is noted from 50 to 250 μm, resulting in reduced cumulative dendritic area. To determine if the dendritic phenotype in FUS-R521C spinal motor neurons
affected synaptic connectivity, we use ChAT (green) and FUS immunostaining to characterize the density of synapses surrounding motor neurons (Betley et al., 2009). Our
results show that FUS proteins are present primarily in neuronal nuclei, but also show extensive colocalization with ChATþboutons and synaptophysin-immunoreactive
presynaptic terminals. Remarkably, the density of ChATþboutons and SIPT showed signiﬁcant reductions in the anterior horn of FUS-R521C spinal cord. To further char-
acterize the synaptic defects, we use electron microscopy (EM) to ascertain the morphology and density of synapses within 100 μm radius of the cell body of spinal motor
neurons, and show that the cell bodies of control motor neurons are surrounded by synaptic terminals arranged as rosette-like structures (Betley et al., 2009). In contrast, the
size of post-synaptic density and the number of synapse per unit area are reduced in FUS-R521C motor neurons. Similar dendrite and synaptic defects are also noted in the
apical and basal dendrites of the pyramidal neurons in layer IV-V of the sensorimotor cortex (Qiu et al., 2014), and neurons in the entorhinal cortex (Huang et al., 2012).
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be pathogenic.
Unlike the severe loss of spinal motor neurons in the SOD1G93A
mice, the neuron loss phenotype in different FUS transgenic
models appears to be more modest. At end stage, FUS-R521C
transgenic mice and rats, and transgenic mice expressing FUS-
R521G or a truncated FUS mutant protein (amino acids 1–359),
show greater than 50% preservation of spinal motor neurons (Ta-
ble 1) (Huang et al., 2011; Qiu et al., 2014; Sephton et al., 2014;
Sharma et al., 2016; Shelkovnikova et al., 2013). The majority of
mutant FUS-R521C proteins are located within the nuclei of spinal
motor neurons in these transgenic animals, with few neurons
showing evidence of FUS-R521C protein aggregates in the cyto-
plasm. The lack of prominent cytoplasmic FUS inclusion in the
FUS-R521C transgenic models is quite different from the pathology
observed in patients with FALS caused by FUS mutations (Huang
et al., 2010; Kwiatkowski et al., 2009; Vance et al., 2009). Another
interesting observation is that few neurons in FUS-R521C trans-
genic rats and wild type FUS transgenic mice show accumulation
of ubiquitin-positive inclusions in the cytoplasm. Curiously, how-
ever, most of the ubiquitin-positive cytoplasmic inclusions do not
contain mutant or wild type FUS proteins (Huang et al., 2011;
Mitchell et al., 2013).
The discrepancy of neuropathology in the rodent models and
human patients raise several intriguing questions regarding thecause and signiﬁcance of FUS-positive cytoplasmic inclusions in
FALS. One possible explanation for the lack of FUSþcytoplasmic
inclusions in transgenic rodent models is that the cytoplasmic
aggregation of wild type or mutant FUS proteins may be age- and
dosage-dependent. Depending on the efﬁciency of nucleus-to-cy-
toplasm translocation for wild type and mutant FUS proteins, the
early postnatal lethality in most of the transgenic mice or rats may
not have given FUS proteins sufﬁcient time to accumulate in the
neuronal cytoplasm. Alternatively, it is possible that mouse spinal
motor neurons may develop inherent homeostatic mechanisms to
maintain the certain level FUS expression (Dini Modigliani et al.,
2014). In this regard, only when expressed at exceedingly high
level using viral vectors, such as AAV1, will the FUS proteins begin
to accumulate in the neuronal cytoplasm (Verbeeck et al., 2012).
Regardless of the mechanism, the observations that transgenic
mice and rats develop severe neurodegenerative phenotypes even
in the absence of prominent FUS proteinopathy in neuronal cy-
toplasm suggest that increase of wild type FUS proteins or the
presence of mutant FUS proteins in nucleus is sufﬁcient to cause
disease, most likely through the perturbations of DNA damage
repair/response and RNA splicing machinery (Qiu et al., 2014;
Wang et al., 2013). Interestingly, FALS-related mutation FUS-R521G
exhibits a drastic shift in binding preference from the intronic
sequences to sequences in the 3′UTR (Hoell et al., 2011).
While the results from the murine models suggest that mutant
Table 1
Summary of FUS loss-of-function and ALS-associated FUS mutations in model organisms.
Mutation Species Targeting methods Phenotypes References
LOF Mouse Knockout – Male sterility Kuroda et al., 2000
– ↑Unpaired & mispaired chromosomal axes in spermatocytes
Knockout – Perinatal lethal Hicks et al., 2000
– Defects in B lymphocytes
– ↑Genomic instability
Conditional knockout – No phenotype in adult neurons Sharma et al., 2016
Drosophila Deletion in caz gene – Pupation and eclosion defects Wang et al., 2011
– Adult caz mutants show reduced survival and locomotor defects
– TBPH cannot rescue caz phenotype
Xenopus Antisense MO – Severe gastrulation defects Dichmann and Harland, 2012
knock-down – RNA-seq: splicing defects in genes in FGF, cell adhesion, and other
major signaling pathways
LOF/GOF Zebraﬁsh Antisense MO – Axon & behavior defects Kabashi et al., 2011
knock-down – Rescued by WT FUS, but not FUS-R521C or FUS-R521H
– Toxic GOF phenotype in FUS-R521H
Antisense MO – Impaired motor activity Armstrong and Drapeau, 2013
– Reduced NMJ synaptic transmission
– FUS-R521H reduces synaptic ﬁdelity
GOF Zebraﬁsh mRNA injection WT FUS, FUS-H517Q – Cytoplasmic mislocalization Bosco et al., 2010
– Stress granule formation-R521G, -R495X or -G515X
GOF Rat Tet-inducible system WT FUS and
FUS-R521C
– ALS-like phenotype Huang et al., 2011
– Early postnatal mortality
Camk2a-tTA inducible WT FUS and
FUS-R521C
– Dendrite defects in neurons in the entorhinal cortex Huang et al., 2012
– Golgi & mitochondria defects
– Protein ubiquitination defects
GOF C. elegans Pan-neuronal promoter – Motor defects, shortened lifespan Murakami et al., 2015
FUS-R514G, -R521G – Neuronal dysfunctions
-R522G, R524S, P525L
GOF Mouse Mouse PrP promoter – ALS-like phenotypes in homozygotes Mitchell et al., 2013
WT human FUS – FUSþ/ubiquitin– cytoplasmic inclusions
GOF Mouse Thy1 promoter – Cytoplasmic FUS aggregates Shelkovnikova et al., 2013,
2014FUS 1-359 – Motor neuron loss
– Disruption of paraspeckle
GOF Mouse FLAG-FUS-R521C transgenic
expression
– ALS-like phenotypes w/ moderate loss of spinal motor neurons Qiu et al., 2014
by Syrian hamster – Severe dendrite/synapse defects
PrP promoter – Neuroinﬂammation
– RNA-seq: transcription & splicing defects in genes for neural
development
GOF Mouse FUS-WT or FUS-R521G – ALS-like phenotypes in FUS-R521G Tg Sephton et al., 2014
transgenic expression – Modest loss of spinal motor neurons
by ubiquitous Cre – Severe dendritic defects
promoter – Neuroinﬂammation
– Dysregulation of mGluR & synaptic proteins
– No neurological phenotype in FUS-WT Tg mice
GOF Mouse FUS-WT, FUS-R521C and – Phenotype FUS-P525L 4 FUS-R521C Sharma et al., 2016
FUS-P525L transgenic – Modest loss of spinal motor neurons
expression from MAPT – Loss of NMJ synapse
locus – Astrogliosis and microgliosis
– No phenotype in FUS-WT Tg mice
GOF Drosophila Global or neural – Severe eye degeneration Lanson et al., 2011
expression of – Pupal mortality & locomotor defects Daigle et al., 2013
human FUS – Cytoplasmic mislocalization Shahidullah et al., 2013
– Stress granule formation
– Synapse defects precede neuro- degeneration
*Abbreviations: LOF: loss of function; GOF: gain of function; MO: morpholino; PrP: prion.
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with wild type FUS proteins and new RNA targets, we are still at
the very early stage of uncovering the mechanism(s) of FUS mu-
tations that contribute to impairments in neuronal survival and
defects in dendritic growth and synaptic connectivity. In Sections
4 and 5, we summarize the recent ﬁndings on the effects of FUS
mutations in DNA damage repair and RNA splicing, which are
likely to have synergistic contributions to the dendritic and sy-
naptic defects. These results not only provide important insights
on the potential target genes, which might be preferentially af-
fected by the DNA damage repair and RNA splicing defects caused
by FUS mutations, they also provide future directions to establish
both in vitro and in vivo approaches to characterize howaccumulation of mutant FUS proteins in neuronal cytoplasm af-
fects ribosomal functions and RNA transport in dendrites and
axons.
3.2. FUS-mediated neurodegeneration in other model organisms
In addition to the rodent models of FUS mutations, results from
other model organisms, including yeasts and Xenopus, have re-
vealed a wealth of information regarding the in vivo functions of
FUS during organismal development, and how FUS mutations may
disrupt these functions and contribute to the neurodegenerative
process. There are several additional studies performed in other
model organisms, including Drosophila melanogaster, C. elegans
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genetic interactions between FUS and other FALS-related genes,
such as TARDBP and SOD1.
Drosophila has a single homolog of FUS, encoded by the cabeza
(caz) gene on X chromosome, that shares 53% amino acid identity
to its mammalian counterpart (Stolow and Haynes, 1995). The
Drosophila Caz protein contains 399 amino acids and is expressed
in neurons, glia and muscle cells. Loss-of-function analyses show
that only 14% of male caz mutant larvae successfully undergo
pupation and eclose to become adults (Wang et al., 2011). The caz
mutants that do survive into adulthood exhibit severe locomotion
phenotype and a markedly reduced survival in postnatal life. The
eclosion phenotype in caz mutants can be rescued by neuron-
speciﬁc transgenic expression of Caz, wild type human FUS
(hFUSWT), hFUSR522H or hFUSP525L at the same expression level,
suggesting that hFUSWT, hFUSR522H and hFUSP525L can functionally
restore the role of Caz during eclosion. However, neuron-speciﬁc
transgenic expression of Caz or hFUSWT only partially restores the
locomotion and longevity phenotype, whereas neither hFUSR522H
nor hFUSP525L is capable of restoring the locomotion or longevity
phenotype. Interestingly, Drosophila tbph mutants lacking TDP-43
homolog TBPH also show similar phenotype in eclosion, locomo-
tion and longevity. Whereas expression of TBPH in caz mutants
cannot rescue loss of Caz phenotype, overexpression of Caz in tbph
mutants restores eclosion, locomotion and longevity. These results
support the model that caz and tbph genetically interact in Dro-
sophila to regulate neuronal development and longevity (Wang
et al., 2011). Several other studies using Drosophila as a model
system also show that expressing mutant human FUS proteins,
hFUSR518K, hFUSR521H or hFUSR521C, in the eye, motor neurons or
the nervous system leads to eye degeneration, defects in loco-
motion and increase in mortality (Lanson et al., 2011). Detailed
analyses of the locomotion defects indicate that mutant FUS pro-
teins cause synaptic defects before the degeneration of motor
neurons. The synaptic defects include disorganization of the pre-
synaptic active zone protein brunchpilot, reduced quantal contents
and miniature presynaptic currents, and reduced synaptic currents
in the postsynaptic muscle cells (Shahidullah et al., 2013).
The effects of FUS in synaptic functions have also been in-
vestigated using the zebraﬁsh larvae as a model system. Antisense
morpholino (AMO) knockdown of FUS in zebraﬁsh causes motor
behavioral defects reﬂected as reduced touch-evoked escape re-
sponse (TEER) and marked reductions in the branching and length
of motor axons (Kabashi et al., 2011). Similar to the observations in
Drosophila, AMO knockdown of FUS and expressing mutant hu-
man FUS proteins in zebraﬁsh also cause defects in synaptic
transmission at NMJ by reducing the presynaptic quantal contents
(Armstrong and Drapeau, 2013).4. Mechanism of FUS mutations in neurodegeneration: DNA
damage defects
4.1. DNA damage and neurodegeneration
Both prokaryotic and eukaryotic organisms use highly evolu-
tionarily conserved mechanisms to repair DNA damages caused by
radiation from the environment or by endogenous sources, such as
free radicals produced within the cells. Mutations in DNA repair
machinery have been linked to hereditary neurodegenerative
diseases (Jackson and Bartek, 2009; McKinnon, 2009; Rass et al.,
2007). For instance, ataxia telangiectasia (AT) is an autosomal re-
cessive, early onset neurodegenerative disease caused by muta-
tions in the ATM gene, which encodes a protein kinase that reg-
ulates the cellular response to DNA double strand breaks (DSBs).
Patients with mutations in the components of the DNA damagesensor complex MRN (MRE11-RAD50-NBS1) also develop severe
neurological symptoms, with hypersensitivity to ionizing radiation
and genome instability. Another DNA damage repair machinery
involves base excision repair (BER), which is the primary me-
chanism that handles spontaneous DNA damage caused by free
radicals and reactive oxygen species (ROS). Patients with muta-
tions in critical components of the BER machinery, including CSA
(also known as excision repair cross-complementing rodent repair
deﬁciency, complementation group 6 or ERCC6), CSB (ERCC8), XPD
(ERCC2) and XPG (ERCC5), develop Cockyane syndrome, char-
acterized by retinal degeneration, microcephaly, deafness and loss
of Purkinje cells in the cerebellum (Cleaver et al., 2009). In addi-
tion to the inherited forms of neurodegenerative diseases, DNA
damage and genomic instability have also been linked to late-
onset neurodegenerative diseases, such as Alzheimer's disease and
Parkinson's disease (Anderson et al., 1996; Bender et al., 2006; Lu
et al., 2004).
4.2. Roles of FUS in DNA damage response and repair
Several studies have implicated FUS in the DNA damage re-
sponse and repair machinery during development and in postnatal
life. For instance, two groups have independently generated mice
lacking FUS (FUS / mutants) and show that FUS deﬁciency con-
sistently leads to a marked increase in DNA damage that affect a
wide range of cell types during perinatal development and in
postnatal life (Table 1) (Hicks et al., 2000; Kuroda et al., 2000).
When maintained in the C57Bl6 background, FUS–/– mice are
perinatal lethal and exhibit severe deﬁciency in B lymphocyte
development. In contrast, FUS / mice maintained in the mixed
129svev;CD1 genetic background survive into adulthood and show
male sterility. Regardless of the genetic background, however, one
consistent phenotype in both independent FUS / mouse lines are
the presence of genomic instability and increased vulnerability to
ionizing irradiation. Consequently, FUS / mice present with in-
creased numbers of unpaired and mispaired chromosomal axes in
pre-meiotic spermatocytes and in B lymphocytes (Hicks et al.,
2000; Kuroda et al., 2000).
The robust genomic instability and increased DNA damage
phenotype in FUS–/– mice raise the intriguing possibility that FUS
might be involved in DNA damage response and repair machinery.
Indeed, FUS has been suggested to be involved in the formation of
D-loops, an essential step in homologous recombination, and
normally presents in chromosome pairing, DNA repair and telo-
meres (Baechtold et al., 1999; Bertrand et al., 1999). Interestingly,
wild type FUS, but not FUS-CHOP fusion protein can be phos-
phorylated by ATM (ataxia-telangiectasia mutated) in response to
DNA double strand breaks (DSBs) (Gardiner et al., 2008). In addi-
tion, FUS has been shown to promote homologous DNA pairing, a
key step in homologous recombination (HR), whereas the onco-
genic fusion protein FUS-CHOP, in which the C-terminal domain of
FUS was replaced by the DNA-binding and leucine zipper dimer-
ization domain of CHOP (Crozat et al., 1993), is unable to promote
DNA pairing. Since the Gly-rich domain is retained in the FUS-
CHOP protein, these data suggest that the N-terminal domain of
FUS may be involved to DNA repair through interaction with other
proteins in the DNA repair machinery. Consistent with this notion,
FUS has been shown to directly interact with CBP/p300, an acet-
yltransferase, through its N-terminal domain, and leads to the
inhibition of CCND1 transcription following DNA damage (Wang
et al., 2008), suggesting that FUS may play multiple roles in re-
sponse to DNA damage. Surprisingly, the ability of FUS to respond
to DNA damage depends on the allosteric interaction with single-
stranded, low copy number long noncoding RNA transcripts (Wang
et al., 2008). Together, these results underscore the unique feature
of FUS as RNA and DNA binding protein in regulating the DNA
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To determine how FUS affects DSB repair, Wang and colleagues
use siRNA to knockdown FUS and show that loss of FUS affects
homologous recombination and non-homologous end joint
(NHEJ)-mediated DSB repairs in both U2OS cells and primary
neurons (Wang et al., 2013). Using γH2AX immunoreactivity as an
early marker of DNA damage and a prerequisite marker for DSB
repair (Fillingham et al., 2006; Pilch et al., 2003), they further
demonstrate that FUS is rapidly recruited to DNA damage sites,
which precedes the accumulation of γH2AX. These results, in-
dependently conﬁrmed by other groups (Mastrocola et al., 2013;
Rulten et al., 2014), suggest that recruitment of FUS to damaged
chromatin is required to elicit an effective DDR. The study by
Rulten and colleagues further show that FUS recruitment to DNA
damage foci is dependent on poly (ADP-ribose) polymerase 1
(PARP1). However, it is unclear if these results indicate the pre-
sence of hierarchy of protein complex formation involving PARP1
and FUS in the assembly of DNA response/repair machinery, or the
requirement of PARP1 is a cell type-speciﬁc phenomenon (Rulten
et al., 2014; Wang et al., 2013). Finally, DSB can induce nucleus-to-
cytoplasm translocation of FUS and causes phosphorylation of FUS
in the C-terminus by DNA-dependent protein kinase (DNA-PK)
(Deng et al., 2014b). These studies provide the ﬁrst molecular clue
for the previous observations that FUS–/– mice exhibit enhanced
radiation sensitivity, growth retardation, immunodeﬁciency, andFig. 4. Mechanisms of wild type and mutant FUS in DNA damage repair/response and
double-stranded breaks, where it interacts with chromatin remodeling factor HDAC1. Alt
HDAC1 and PARP1. Due to the defects in DNA repair/response machinery, neurons in FU
and the presence of double-stranded breaks). (B) In addition to its role in DNA damage re
Results from CLIP-RT-PCR and protein-RNA interactions in EMSA assays show that both
Bdnf exon-intron boundaries. Whereas the equilibrium of wild type FUS-RNA interaction
complexes that are more difﬁcult to dissociate. (Figure adapted from Qiu et al., 2014, wincreased genomic instability (Hicks et al., 2000; Kuroda et al.,
2000).
4.3. FUS mutations and HDAC-dependent DNA damage response/
repair
Given the critical role of FUS in DNA damage response/repair, it
is interesting to note that FALS-associated mutations in FUS do not
affect the recruitment of mutant FUS proteins to DNA damage foci.
Rather, the mechanism by which FUS regulates DNA damage re-
pair machinery depends on its ability to directly interact with
chromatin remodeling factor histone deacetylase 1 (HDAC1),
which plays fundamental role in DNA repair and the maintenance
of genomic stability (Fig. 4A). Deﬁciency in HDAC1 and the closely
related HDAC2 causes severe hypersensitivity to DNA damaging
agents and persistent phenotypes related to DNA repair defects,
including dysregulation of histone acetylation, abnormalities in
heterochromatin formation, and aberrant expansion and re-con-
densing of the chromatin structure in DNA repair process (Dinant
et al., 2008; Lukas et al., 2011; Miller et al., 2010). Interestingly, loss
of HDAC1 has been reported to sensitize neurons to DNA damage
and induce aberrant cell cycle re-entry, while the overexpression
of HDAC1 protects neurons from genotoxic agents (Dobbin et al.,
2013; Kim et al., 2008). Indeed, both neurons with FUS deﬁciency
and HDAC1–/– neurons exhibit increased DNA damage followingRNA splicing. (a) Wild type FUS is rapidly recruited to DNA damage foci caused by
hough FUS-R521C can still be recruited to DNA damage foci, it fails to interact with
S-R521C transgenic mice show increased DNA damage (indicated by blue asterisks
pair, several lines of evidence indicate that FUS can also regulate pre-mRNA splicing.
wild type FUS and FUS-R521C can interact with selective oligoribonucleotides from
s appears to be more dynamic, FUS-R521C tends to form more stable protein-RNA
ith permissions from the Journal of Clinical Investigation.).
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supporting the notion that the interaction between FUS and
HDAC1 plays an important role in maintaining genome stability
and integrity in neurons.
The fact that FALS mutations are transmitted in an autosomal
dominant manner and FALS mutations do not affect FUS recruit-
ment to DNA damage foci lead to the hypothesis that mutant FUS
proteins may have dominant-negative effect that interferes with
its interaction with HDAC1 and the subsequent assembly of DNA
repair machinery (Fig. 4A). Indeed, structure-function analyses
show that the Glycine-rich domain (amino acids 156–262) and
C-terminal domain (amino acids 450–526) of FUS are required for
FUS–HDAC1 interaction (Wang et al., 2013). Remarkably, these two
domains in FUS harbor most of the FALS mutations, and FUS
mutations in these two domains, including FUS-R244C, FUS-R514S
and FUS-R521C, show impaired interaction with HDAC1 and re-
duced DSB repair efﬁciency when expressed in cells. Consistent
with these results, wild type FUS can be detected in a protein
complex with HDAC1 in the control spinal cord tissues. In contrast,
protein extracts from FUS-R521C transgenic mice show no de-
tectable complex formation between FUS-R521C and HDAC1 (Qiu
et al., 2014). Interestingly, the presence of FUS-R521C almost
completely abolishes the protein–protein interaction betweenwild
type FUS and HDAC1 in FUS-R521C transgenic mice. This dominant
effect of FUS-R521C is due to the abnormal gain-of-function
property of the mutant FUS-R521C protein in forming more stable
complex with wild type FUS protein in both HEK293T cells and in
FUS-R521C transgenic mice. Consistent with these results, spinal
motor neurons and cortical neurons in FUS-R521C transgenic mice
and in patients with FUS-R521C or FUS-P525L mutation show a
robust increase of γH2AX staining (Qiu et al., 2014; Wang et al.,
2013).
The demonstration that DNA damage repair defects contribute
to the pathogenesis of neurodegeneration caused by FUS muta-
tions further underscores the critical role of DNA damage repair in
neurodegenerative conditions. Indeed, several previous studies
have shown that increased levels of 8-hydroxydeoxyguanosine (8-
OHdG) residues, a marker of oxidative DNA damage, can be
identiﬁed in the spinal cord of both sporadic and familial ALS
patients (Ferrante et al., 1997). Age-related motor neuron degen-
eration has been observed in mice lacking the DNA repair protein
ERCC1, suggesting that the accumulation of DNA damage con-
tributes to the motor neuron vulnerability (de Waard et al., 2010).
To determine whether FUS mutations cause widespread or selec-
tive target genes, Qiu and colleagues performed a quantitative
PCR-based formamidopyrimidine-DNA glycosylase (FPG), a based
excision repair enzyme, assay to identify oxidized purine residues
in a highly selected group of neural genes (Qiu et al., 2014). Their
results show that signatures of DNA damage can be detected in the
5′ and 3′ UTR of genes that involve in synaptic transmission (NR2A
and GluR2) and dendritic growth (Bdnf). One interesting caveat is
that the DNA damage in these genes appears to be more promi-
nent in the cortex than in the spinal cord. Hence, future experi-
ments are needed to reveal additional targets at the genome-wide
level. While these results suggest that perturbations to multiple
signaling pathways may converge on the DNA damage repair de-
fects leading to neurodegeneration, it is important to note that
DNA damage due to defects in oxidative stress and nucleotide
excision repair is quite different from that caused by double
stranded DNA breaks or defects in the ATM pathways. Finally, it is
unclear why motor neurons are more susceptible to FUS mutations
despite the fact that almost all neurons express mutant FUS pro-
teins and the evidence of DNA damage can also be detected in
cortical neurons of FUS-R521C transgenic mice and human disease
tissues (Qiu et al., 2014; Wang et al., 2013). Such “selective vul-
nerability” is a common theme in neurodegenerative diseases. Onepotential mechanism is that motor neurons may produce ex-
cessively higher amount of mitochondrial reactive oxygen species,
which may create a vicious cycle that further promotes the accu-
mulation of DNA damage repair defects (Cleaver et al., 2013; Rul-
ten et al., 2014).5. Mechanism of FUS mutations in neurodegeneration: RNA
splicing defects
5.1. Effects of FUS mutations in RNA transcription/splicing defects
The causal link between FUS mutations and DNA damage de-
fects provides critical mechanistic insights to neurodegeneration
because the process to repair DNA damage is tightly coupled to
transcription through regulating the activity of RNA polymerase II
and the subsequent RNA processing, including RNA splicing and
transport (Cleaver et al., 2009; Kornblihtt et al., 2004; Munoz et al.,
2009). Furthermore, a plethora of evidence supports that RNA
transcription in the eukaryotic cells is a highly dynamic and tightly
regulated process that involves multiple intricately connected
steps, including splicing of pre-mRNA and transport of mature
mRNA to its ﬁnal destinations (Moore and Proudfoot, 2009; Reed
and Hurt, 2002). In the nervous system, these regulatory me-
chanisms are known to generate a vast diversity of RNA transcripts
that control cell fate determination, axon guidance, dendritic
growth and synaptic functions (Li et al., 2007; Martin and
Ephrussi, 2009). Perturbations to these critical mechanisms have
been implicated in neuromuscular diseases, neurodevelopmental
disorders and neurodegenerative diseases (Cooper et al., 2009).
Consistent with these ﬁndings, two recent studies show that
both human patients with FUS-R521C or FUS-P525L mutation, and
FUS-R521C transgenic mice exhibited evidence of DNA damage in
cortical neurons and spinal motor neurons (Qiu et al., 2014; Wang
et al., 2013). These results indicate that the FUS-R521C transgenic
mice provide an invaluable system to identify neural genes im-
plicated in DNA damage during neurodegeneration (Graff et al.,
2012; Lu et al., 2004). Indeed, a PCR-based screening approach
shows that the 5′ non-coding exons of the mouse Bdnf gene, which
contain transcriptional start sites and are required splicing of long
intronic sequences to generate mature Bdnf mRNA, consistently
exhibit evidence of DNA damage. These results lead to the iden-
tiﬁcation of retentions of 5’ splice junctions in the Bdnf mRNA and
defects in transporting Bdnf mRNA to distal dendrites. Using
electrophoretic mobility shift assays (EMSA), it is further demon-
strated that, compared to wild type FUS, mutant FUS-R521C pro-
teins form more stable protein-RNA complex to 5′ splice junction
and the 3′UTR sequences of Bdnf pre-mRNA (Qiu et al., 2014)
(Fig. 4B). These results support the idea that FALS-associated FUS
mutation FUS-R521C exhibits aberrant gain-of-function properties,
including forming more stable protein-protein interactions with
the endogenous wild type FUS and more stable protein-RNA
complex, which most likely alter the ability of FUS to recruit DNA
damage repair machinery and the equilibrium of the interactions
between FUS and RNA in the splicing machinery, respectively
(Fig. 4) (Qiu et al., 2014; Wang et al., 2013). Similar phenotypes of
FUS mutations in DNA damage repair and RNA splicing machinery
have been reported in several other studies using biochemical, cell
biology and bioinformatics analyses (Hoell et al., 2011; Mastrocola
et al., 2013; Zhou et al., 2014).
Given the highly efﬁcient process in RNA splicing, the ob-
servations that FUS-R521C can form more stable protein-RNA
complex raise the intriguing question as to whether this gain-of-
function property may have more widespread intron retention
effects on the transcriptomes or only affect a selective subset of
target genes. To distinguish these two possibilities, Qiu and
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FUS-R521C spinal cord using RNA-seq and show two primary
defects involving the transcription and RNA splicing in selective
genes that are critical for dendritic growth and synaptic functions
(Qiu et al., 2014). For instance, RNA-seq results in the spinal cord of
FUS-R521C mutants show perturbations in the expression or
splicing of genes involved in the organization of extracellular
matrix, including members of the collagen and cadherin gene fa-
milies that regulate the speciﬁcity of axonal projection and target
innervation (Robles and Baier, 2012; Sanes and Yamagata, 2009).
Interestingly, similar targets have also been identiﬁed in the RNA-
seq analyses of FUS MO-treated Xenopus morphants (Dichmann
and Harland, 2012), suggesting that FUS-R521C phenotype may
recapitulate certain transcriptional and RNA splicing defects in FUS
loss-of-function mutants. Another intriguing feature of the RNA-
seq results in FUS-R521C spinal cord is that many target genes in
the extracellular matrix assembly GO categories (GO:0005581,
GO:0005201, GO:0005578 and GO:0031012) have also been
shown to be transcriptional targets of DNA damage response gene
Cockyane syndrome B (CSB) and HDAC1 (Newman et al., 2006),
and are frequently misregulated and misspliced in the motor
neurons of SALS patients (Rabin et al., 2010). While these results
are correlative, they raise the interesting possibility that the re-
cruitment of FUS, HDAC1 and CSB may constitute a critical step in
the repair of damaged DNA in FALS caused by FUS mutations and
in SALS.
Finally, one remarkable feature in the spinal cord of FUS-R521C
transgenic mice is the up-regulation of genes that are functionally
related to immune response, complement activation and chemo-
taxis (Qiu et al., 2014). Consistent with these ﬁndings, the FUS-
R521C spinal cord show pronounced microgliosis. Since neither
wild type FUS or FUS-R521C proteins can be detected in the mi-
croglia, these results support the idea that non-cell autonomous
mechanisms, triggered by damaged neurons or reactive astroglia,
may activate microglia and contribute to the neurodegeneration in
ALS. Interestingly, similar non-cell autonomous mechanisms have
been reported in the mutant SOD1 models (Boillee et al., 2006a;
Boillee et al., 2006b). Alternatively, the defects in DNA damage
repair and RNA splicing caused by mutant FUS-R521C may occur in
glia cells, which promotes astroglial activation and/or degenera-
tion of oligodendroglia, further contributing to the dendritic loss
and synaptic degeneration of spinal motor neurons in FUS-R521C
mice.
5.2. Mechanisms of FUS mutations in RNA splicing machinery
Several studies indicate that FUS can physically interact with
SMN and U1 snRNP, and that loss of FUS or expressing FALS-as-
sociated FUS mutations disrupts the organization of Gemini of
Cajal bodies (Gems), where the presence of TDP-43, FUS and an-
other fatal motor neuron disease gene product SMN are required
to regulate the assembly of the Gems in several different cell types
(Battle et al., 2006; Sun et al., 2015; Yamazaki et al., 2012). Con-
sistent with these ﬁndings, FUS / hippocampal neurons show a
near complete loss of Gems. Interestingly, the integrity of Gems
and splicesome is severely perturbed in the spinal motor neurons
of patients with sporadic ALS, which most likely is due to the loss
of nuclear TDP-43 and prominent up-regulations of U snRNAs and
snRNPs (Tsuiji et al., 2013). In addition to its roles in the organi-
zation of splicesome, FUS is implicated in the integrity of para-
speckles, which are subnuclear structures that regulate gene ex-
pression by nuclear retention of RNA (Bond and Fox, 2009). The
core paraspeckle proteins include DBHS (Drosophila melanogaster
behavior, human splicing) proteins, PSF/SFPQ, P45NRB/NONO, and
PSPC1. In addition, a long noncoding RNA (lncRNA) NEAT1 is also
required to maintain the integrity of paraspeckles. In a recentstudy, FUS and TDP-43 are shown to interact with NEAT1 (Nishi-
moto et al., 2013), raising the possibility that perturbations to both
proteins may disrupt the integrity or maintenance of paraspeckles.
Consistent with this idea, spinal motor neurons in transgenic mice
expressing truncated FUS mutant protein (amino acids 1–359)
show cytoplasmic aggregates of P45NRB/NONO. Although confocal
images from these transgenic neurons indicate that P45NRB/
NONO proteins and mutant FUS proteins are in close proximity, it
is unclear whether the presumed complex between P45NRB/
NONO and FUS are disrupted by the presence of mutant FUS
proteins (Shelkovnikova et al., 2013). It is also unclear if the
number and distribution of paraspeckles are disrupted in the
spinal motor neurons of these transgenic mice and in patients
with FALS or SALS. Another alternative mechanism for mutant FUS
proteins to interfere with the integrity of paraspeckles is by al-
tering the expression of lncRNA NEAT1. Indeed, RNA-seq analyses
of spinal cord from FUS-R521C transgenic mice show that the
NEAT1 levels are 2–3 folds higher than that in the age-matched
controls (Qiu et al., 2014).6. Future directions
6.1. Hierarchy of FUS mutations and proteinopathy
The discovery of dominant FUS mutations as one of the major
causal links for FALS has opened up new windows to under-
standing the pathogenesis of ALS. Judging from the biophysical
properties of FUS, it is tempting to propose that the FALS-asso-
ciated FUS mutations alter the liquid-solid phase transition in FUS
and thereby dominantly interfere with the ability of wild type FUS
in DNA damage repair and RNA splicing, leading to both structural
and functional defects in dendritic/axonal growth and synaptic
transmission. The fundamental effects of mutant FUS proteins can
be attributed to its aberrant gain-of-function properties that alter
the homeostasis of the interactions of wild type FUS and its the
interacting partners, including proteins, pre-mRNAs and lncRNAs,
and the DNA damage response/repair and RNA splicing machinery.
In many aspects, these gain-of-function properties truly reﬂect
broad and essential roles of wild type FUS in the embryonic and
postnatal development, and in the maintenance of the organisms
and the nervous system.
Notwithstanding these new insights into FUS mutations, it re-
mains a challenge to determine how these new mechanisms help
in understanding the pathogenesis of FALS and SALS. With the
availability of transgenic models for FUS and TDP-43, we may
begin to determine whether mutations in FUS or TDP-43 target
similar or divergent mechanisms that eventually lead to neuro-
degeneration. This is especially important given that TDP-43 pro-
teinopathy is a major neuropathological feature not only in FALS,
but also in SALS. Several directions for future research include
(1) whether FUS and TDP-43 proteins use similar or different in-
tracellular trafﬁcking mechanisms for their transport in and out of
the neuronal nucleus, (2) how FUS and TDP-43 proteinopathies
promote degeneration in spinal motor neurons and other types of
neurons, (3) how FUS and TDP-43 mutations might cause non-cell
autonomous mechanisms to promote glial pathology, and
(4) whether patient-speciﬁc induced pluripotent stem cell (iPSC)-
derived neurons can provide a new model system more closely
related to human disease. Indeed, the combined strengths of using
iPSC-derived neurons and model organism Drosophila have led to
the identiﬁcation of novel functions of TDP-43 in mRNA transport
in axons (Alami et al., 2014). Future studies using similar ap-
proaches can also provide more insights to unravel the mechan-
isms and their hierarchical interactions in the pathogenesis of
human diseases. The iPSC approach will also provide important
Y. Shang, E.J. Huang / Brain Research 1647 (2016) 65–7876tools to identify potential therapeutic targets that are speciﬁc for
different mutations in FUS-mediated FALS.
6.2. The expanding repertoire of RNA machinery in
neurodegeneration
The identiﬁcation of mutations in FUS, TARDBP and C9ORF72 in
ALS and FTD-ALS has expanded the landscape of neurodegenera-
tive diseases caused by defects in RNA metabolism machinery.
These studies raise the intriguing questions that FUS, TARDBP and
C9ORF72 may be just tips of an iceberg, and that dysregulations in
RNA machinery may have broader roles in other neurodegenera-
tive diseases. Indeed, results from several recent studies indicate
that the answers to both questions are positive. For instance,
mutations in the prion-like domains of hnRNPA2B1 and hnRNA-
PA1 accelerate ﬁlamentous protein aggregate formation, increase
the propensity of stress granule formation in neuronal cytoplasm
and can contribute to the pathology in patients with multisystem
proteinopathy and ALS (Kim et al., 2013; Molliex et al., 2015).
Furthermore, chemical mutagenesis screens for recessive muta-
tions (Neuroscience Mutagenesis Facility) have reported two mu-
tations, nmf291 and nmf205, that result in neurological pheno-
types. The nmf291 allele is caused by a 5-nucleotide deletion in the
U2 snRNA, which leads to profound dysregulation in RNA splicing
and an age-dependent, progressive degeneration of the cere-
bellum (An et al., 2008). In contrast, the nmf205 mutation results
in loss of GTPBP2 due to a point mutation in the consensus splice
donor site of intron 6 of Gtpbp2, leading to missplicing of Gtpbp2
mRNA and a premature stop codon. Since GTPBP2 is an essential
binding partner for the ribosome recycling protein pelota, loss of
GTPBP2 results in widespread ribosomal stalling and profound
age-dependent neurodegeneration in the cerebellum of nmf205
mutants (Ishimura et al., 2014). Finally, two recent studies show
that mutations in the human cleavage and polyadenylation factor
subunit 1 (CLP1) gene, which encodes a multifunctional kinase
implicated in the maturation of tRNA, mRNA and siRNA, cause
severe neurodegeneration in the cerebellum (Karaca et al., 2014;
Schaffer et al., 2014). Consistent with these ﬁndings, mouse mu-
tants that express kinase-dead mutant CLP1 show neurodegen-
eration, characterized by a progressive loss of spinal motor neu-
rons, axonal degeneration in the peripheral nerves, and denerva-
tion of neuromuscular junctions, leading to impaired motor
function, muscle weakness, paralysis and fatal respiratory failure
(Hanada et al., 2013). Together, these ﬁndings further expand and
reinforce the critical role of RNA metabolism in maintaining the
normal functions of the nervous system.Grant sponsors
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